Pharmacognosy intro
Andrographis derives its extraordinary anti-inflammatory potency from andrographolide, a labdane diterpenoid present at 1-4% dry weight (leaves up to 4%), supported by neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, andrograpanin, and andrographiside. Standardized extracts typically contain 10-30% andrographolide, with the KalmCold/AP-Bio formulation standardized to 30% total andrographolides and the Kan Jang preparation combining andrographis with Eleutherococcus. The primary mechanism is remarkable: andrographolide forms a covalent adduct with the reduced cysteine 62 (Cys62) of the p50 subunit of NF-kappaB, physically blocking its DNA-binding capacity and shutting down downstream inflammatory gene transcription. It also suppresses MAPK/PI3K-Akt signaling by inhibiting phosphorylation of MEK1/2, ERK1/2, and Akt cascades, and reduces expression of iNOS, COX-2, E-selectin, and pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. Immunomodulatory effects include enhanced phagocytic activity of macrophages and stimulation of both humoral and cell-mediated immune responses at moderate doses. Clinical evidence includes a randomized controlled trial (n=158) showing 1200 mg daily for 5 days significantly reduced cold symptoms versus placebo by day 2, with a safety meta-analysis finding serious adverse events extremely rare at 0.02 per 1000 patient-years.